Z
Zylox Medical
Interventional medical devices for neurovascular and peripheral diseases
About Zylox Medical
Zylox-Tonbridge Medical Technology Co., Ltd. is a China-based, publicly-traded company specializing in the neurovascular and peripheral interventional medical device market. The company was founded in November 2012 by Dr. Jonathon Zhong Zhao, who serves as Chairman and CEO. Dr. Zhao has over two decades of experience in the pharmaceutical and medical device industries, including R&D on drug-eluting stents and drug-coated balloons.
The company was established in Hangzhou as Zylox Medical Devices Co., Ltd., initially focusing on peripheral vascular intervention. In 2016, Zhuhai Ton-Bridge Medical Tech was founded to focus on neurovascular intervention. The two companies officially merged in 2018, creating Zylox-Tonbridge Medical Technology Co, Ltd. A significant milestone was achieved on July 5, 2021, when the company was listed on the Main Board of the Hong Kong Stock Exchange under the stock code 2190.HK.
Zylox-Tonbridge operates as a fully integrated medical device company with strong in-house research and development, manufacturing, and commercialization capabilities. Its business model focuses on providing a comprehensive portfolio of solutions for physicians and patients. Revenue is generated through the sale of its medical devices, with a distribution network covering over 3,000 hospitals in China and a growing international presence. The company's product portfolio includes over 60 products and candidates, such as the Thrombite™ Clot Retriever Device, Ultrafree™ Drug Coated PTA Balloon Catheter, and the Kylin™ Flow Diverter. The company also engages in strategic partnerships, such as its collaboration with Avinger, Inc. to commercialize OCT imaging-guided devices in Greater China and leverage cost-efficient manufacturing for global sales.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- Hangzhou, China
- Employees
- 33
- Open positions
- None listed
- Dealroom signal
- 55.8/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Surgery, Neurology, Catheters, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Oct 2020 | $45M | $180M | SDIC Fund Management · Zheshang Venture Capital · OrbiMed | — |
| SERIES BOther financing | Jan 2019 | $15M | $59M | SDIC Fund Management | — |
Growth signals
Latest recorded traffic for Zylox Medical is 840 monthly website visits, down 47.5% over the last three months. Zylox Medical's team grew 26.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
SDIC Fund Management- SCSDIC Fund Management Company
Series B and later2 investors entered at this stage
OrbiMed- ZCZheshang Venture Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Zylox Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Zylox Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.